Overview of the transactions
Beam Therapeutics Inc. (NASDAQ: BEAM) reported that Chief Executive Officer John M. Evans sold a combined 50,000 shares of the company’s common stock across March 30 and March 31, 2026, for approximately $1.1 million. The sales were executed at weighted average prices that ranged from $22.3692 to $22.7634. Specifically, Evans sold 25,000 shares on March 30 and an additional 25,000 shares on March 31.
Concurrent acquisitions by the CEO
On those same dates, Evans acquired 50,000 shares at $0.67 per share for a total outlay of $33,500. Additionally, on March 31 he acquired 90,000 shares at no cost. Following the completed transactions, Evans directly holds 1,076,667 shares of Beam Therapeutics common stock. He also retains indirect ownership of 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
Share price and volatility metrics
At the time of the report the stock was trading at $24.21, representing a 79% increase from its 52-week low of $13.53. InvestingPro data cited in the report indicates the share exhibits elevated volatility, with a beta of 2.17.
Clinical and analyst developments
Separately, Beam Therapeutics announced publication of results from its Phase 1/2 BEACON clinical trial evaluating risto-cel for the treatment of sickle cell disease. The trial, which involved 31 patients, was highlighted in The New England Journal of Medicine. Beam also reported clinical data in alpha-1 antitrypsin deficiency (AATD) that identified 60 mg as the pivotal dose to carry forward in development.
Those clinical updates were followed by several analyst reactions. Bernstein SocGen Group reiterated an Outperform rating and maintained a $40 price target. Leerink Partners increased its price target to $47 from $42 while keeping an Outperform rating, citing the updated Phase 1/2 data for BEAM-302. William Blair reiterated an Outperform rating, noting the 60 mg cohort produced the highest mean serum AAT level reported clinically to date. Clear Street reaffirmed a Buy rating and set a $37 price target, emphasizing the confirmation of the optimal dose for pivotal development.
Research resources
For investors seeking further valuation and financial analysis, the report referenced InvestingPro, which offers Pro Research Reports covering over 1,400 U.S. equities.
Context and implications
The combination of insider selling, simultaneous low-cost acquisitions and no-cost awards, a materially higher recent share price relative to the 52-week low, and the company’s reported clinical progress make for a multi-faceted disclosure. The reported analyst actions reflect continued market attention to Beam’s clinical data and dose selection for pivotal development.